Real-life use of remdesivir in hospitalized patients with COVID-19.
Rev Esp Quimioter
; 34(2): 136-140, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-33675220
ABSTRACT
OBJECTIVE:
Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain.METHODS:
We performed a descriptive study of all patients admitted for ≥48 hours with confirmed COVID-19 who received remdesivir between the 1st of July and the 30th of September 2020.RESULTS:
A total of 123 patients out of 242 admitted with COVID-19 at our hospital (50.8%) received remdesivir. Median age was 58 years, 61% were males and 56.9 % received at least one anti-inflammatory treatment. No adverse events requiring remdesivir discontinuation were reported. The need of intensive care unit admission, mechanical ventilation and 30-days mortality were 19.5%, 7.3% and 4.1%, respectively.CONCLUSIONS:
In our real-life experience, the use of remdesivir in hospitalized patients with COVID-19 was associated with a low mortality rate and good safety profile.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Monofosfato de Adenosina
/
Alanina
/
Tratamento Farmacológico da COVID-19
/
Pacientes Internados
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Rev Esp Quimioter
Assunto da revista:
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2021
Tipo de documento:
Article